http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강정훈,양상미,임수빈,정제훈 대한신경손상학회 2019 Korean Journal of Neurotrauma Vol.15 No.1
Objective: Osteoporosis is one of the most common causes of vertebral compressionfractures (VCFs). Teriparatide, a recombinant human parathyroid hormone, is the frstanabolic agent for the treatment of osteoporosis. The aim of this study was to determinewhether 3 months of teriparatide could be effective for patients with osteoporotic VCF at thethoracolumbar spine. Methods: We reviewed 25 patients with thoracolumbar osteoporotic compression fracturesbetween July 2012 and October 2016 who could be followed up for more than 1 year. Patientswere divided into 2 groups depending on the use of teriparatide: 14 patients receivedteriparatide through subcutaneous injection (group I) and 11 patients did not receiveteriparatide (group II). Demographic data, bone mineral density, hospitalization period,changes in the visual analogue scale (VAS) score, body mass index, and medical historysuch as smoking, alcohol, diabetes, and steroid usage were reviewed. Radiographs were alsoreviewed to evaluate vertebral body compression percentages and kyphotic angles. Results: Overall changes of VAS score between injury and follow-up were statisticallyimproved in both groups at 2 to 3 weeks post-injury. However, difference in VAS improvementat a specifc time between the 2 groups was not statistically signifcant. Overall kyphoticangle and compression percentage between injury and follow-up time were increasedin group II than those in group I, although the difference between the 2 groups was notstatistically signifcant. Conclusion: Three-month of teriparatide did not show protective effects on progression offractured vertebral body collapse or kyphotic changes in patients with osteoporosis